News
PCRX
13.85
-5.65%
-0.83
Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
Simply Wall St · 1d ago
Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma
Seeking Alpha · 1d ago
Weekly Report: what happened at PCRX last week (0826-0830)?
Weekly Report · 5d ago
Weekly Report: what happened at PCRX last week (0819-0823)?
Weekly Report · 08/26 09:11
Weekly Report: what happened at PCRX last week (0812-0816)?
Weekly Report · 08/19 09:10
Will Insiders Be Tempted To Buy More PCRX At The New 52-Week Low?
NASDAQ · 08/13 17:07
Pacira BioSciences Cut to Sell From Buy by Truist Securities
Dow Jones · 08/13 14:11
Pacira BioSciences Price Target Cut to $8.00/Share From $30.00 by Truist Securities
Dow Jones · 08/13 14:11
Truist Securities Downgrades Pacira BioSciences to Sell, Lowers Price Target to $8
Benzinga · 08/13 14:00
PACIRA BIOSCIENCES INC <PCRX.O>: TRUIST SECURITIES CUTS TARGET PRICE TO $8 FROM $30
Reuters · 08/13 11:02
PACIRA BIOSCIENCES INC <PCRX.O>: TRUIST SECURITIES CUTS TO SELL FROM BUY
Reuters · 08/13 11:02
Pacira Pharmaceuticals (PCRX) Gets a Hold from Barclays
TipRanks · 08/13 08:47
U.S. RESEARCH ROUNDUP- Apollo, Blackstone, Hershey
Reuters · 08/13 07:22
Pacira downgraded by J.P. Morgan, Piper, RBC, Raymond James
Seeking Alpha · 08/12 19:27
Noteworthy Monday Option Activity: WING, OXY, PCRX
NASDAQ · 08/12 19:19
The 1-Minute Market Report August 10, 2024
Seeking Alpha · 08/12 18:44
Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path
Benzinga · 08/12 18:19
Where Pacira BioSciences Stands With Analysts
Benzinga · 08/12 18:00
Pacira BioSciences Cut to Sector Perform From Outperform by RBC Capital
Dow Jones · 08/12 14:29
Pacira BioSciences Price Target Cut to $14.00/Share From $37.00 by RBC Capital
Dow Jones · 08/12 14:29
More
Webull provides a variety of real-time PCRX stock news. You can receive the latest news about Pacira Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About PCRX
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.